Compare USGO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USGO | NTHI |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | 10 | 5 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 139.1M |
| IPO Year | N/A | N/A |
| Metric | USGO | NTHI |
|---|---|---|
| Price | $8.26 | $5.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.75 | $15.00 |
| AVG Volume (30 Days) | 52.3K | ★ 64.9K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.42 | $3.20 |
| 52 Week High | $17.98 | $12.99 |
| Indicator | USGO | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 54.49 |
| Support Level | $7.55 | $4.17 |
| Resistance Level | $9.80 | $5.90 |
| Average True Range (ATR) | 0.64 | 0.60 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 28.61 | 61.15 |
US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.